SARS-CoV-2 drives NLRP3 inflammasome activation in human microglia through spike proteinEduardo A. Albornoz, Trent M. Woodruff, Rhys Parry et al.|Molecular Psychiatry|2022Cited by 178
Preclinical development of a molecular clamp‐stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2Daniel Watterson, Keith J. Chappell, Danushka K. Wijesundara et al.|Clinical & Translational Immunology|2021Cited by 62
Molecular clamp stabilised Spike protein for protection against SARS-CoV-2Daniel Watterson, Keith J. Chappell, Danushka K. Wijesundara et al.|Unknown|2020Cited by 15
SARS-CoV-2 drives NLRP3 inflammasome activation in human microglia through spike-ACE2 receptor interactionEduardo A. Albornoz, Trent M. Woodruff, Alberto A. Amarilla et al.|bioRxiv (Cold Spring Harbor Laboratory)|2022Cited by 8
Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18–55 years or ≥56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trialKeith J. Chappell, Trent P. Munro, Francesca L. Mordant et al.|EBioMedicine|2023Cited by 6